Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foretinib in Genomic Subpopulations of NSCLC
NCT02034097Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of foretinib in non-small cell lung cancer (NSCLC), sponsored by GSK. Planned start Apr 2014; status: withdrawn.
02
Drugs
foretinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02034097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034097.